Stock listing

NASDAQ:DARE Dare Bioscience, Inc. Stock

Home listing (NASDAQ) of Dare Bioscience, Inc.

Follow Dare Bioscience, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:DARE

$0.407 USD -0.043 (-9.5%)

Close on Nov 20, 2026

Past year -75.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.407 – $0.487 USDNov 20, 2026
Volume
173,237 sharesNov 20, 2026
Market cap
$8.01M USDAt the close on Nov 20, 2026 · price × 19.67M shares outstanding
52-week range
$0.407 – $3.780 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$179,764 USDMedian day 165,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Dare Bioscience, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:DARE · Home$0.407 USD-0.043 (-9.5%)173,237$0.450$0.487$0.407$0.450Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:DARE · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.407-0.043-9.5%$0.450$0.487$0.407173,237
$0.450+0.021+4.9%$0.436$0.510$0.420295,366
$0.429-0.155-26.6%$0.580$0.588$0.415923,226
$0.584-0.073-11.1%$0.694$0.700$0.584201,443
$0.657+0.013+2.0%$0.650$0.695$0.63074,397
$0.644-0.050-7.2%$0.680$0.700$0.64039,728
$0.694+0.002+0.3%$0.709$0.715$0.69097,900
$0.692+0.012+1.8%$0.699$0.710$0.678160,700
$0.680+0.041+6.4%$0.651$0.680$0.640102,900
$0.639+0.015+2.4%$0.632$0.650$0.62053,000
$0.624-0.038-5.7%$0.669$0.680$0.610146,600
$0.662+0.012+1.8%$0.660$0.690$0.630228,300
$0.650-0.005-0.8%$0.653$0.660$0.620138,900
$0.655-0.045-6.4%$0.739$0.739$0.646206,300
$0.700+0.018+2.6%$0.703$0.703$0.670651,500
$0.682+0.002+0.3%$0.670$0.698$0.66446,800
$0.680+0.017+2.6%$0.680$0.680$0.66346,100
$0.663+0.019+3.0%$0.643$0.684$0.64351,600
$0.644-0.002-0.3%$0.668$0.675$0.64050,500
$0.646-0.006-0.9%$0.640$0.666$0.63856,500
$0.652-0.036-5.2%$0.685$0.713$0.625327,900
$0.688-0.001-0.1%$0.680$0.712$0.67324,600
$0.689-0.017-2.4%$0.723$0.730$0.670217,700
$0.706-0.019-2.6%$0.727$0.738$0.680252,000
$0.725-0.015-2.0%$0.739$0.740$0.71377,200
$0.740+0.011+1.5%$0.730$0.746$0.72096,900
$0.729-0.019-2.5%$0.743$0.743$0.72061,000
$0.748-0.002-0.3%$0.786$0.786$0.730116,100
$0.750-0.023-3.0%$0.770$0.790$0.73881,600
$0.773+0.001+0.1%$0.790$0.790$0.76069,600
$0.772-0.018-2.3%$0.786$0.800$0.755165,800
$0.790-0.043-5.2%$0.814$0.819$0.790113,200
$0.833-0.010-1.2%$0.830$0.880$0.83088,400
$0.8430.0000.0%$0.833$0.869$0.831157,200
$0.843-0.008-0.9%$0.869$0.878$0.822147,300
$0.851-0.002-0.2%$0.860$0.870$0.830134,800
$0.853+0.038+4.7%$0.800$0.880$0.768277,700
$0.815+0.065+8.7%$0.787$0.867$0.736644,400
$0.750-0.026-3.4%$0.790$0.816$0.701697,300
$0.776+0.035+4.7%$0.770$0.790$0.746119,100
$0.741-0.066-8.2%$0.802$0.846$0.712469,500
$0.807-0.043-5.1%$0.850$0.870$0.80099,700
$0.850+0.040+4.9%$0.810$0.880$0.810245,500
$0.810+0.026+3.3%$0.820$0.840$0.796279,900
$0.784+0.036+4.8%$0.793$0.810$0.766229,200
$0.748+0.022+3.0%$0.745$0.776$0.745153,200
$0.726-0.004-0.5%$0.732$0.759$0.724135,400
$0.730-0.006-0.8%$0.741$0.771$0.720107,200
$0.736+0.030+4.2%$0.706$0.750$0.691426,100
$0.706+0.001+0.1%$0.717$0.723$0.70593,700
$0.705-0.012-1.7%$0.700$0.725$0.700102,500
$0.717+0.004+0.6%$0.729$0.730$0.691173,400
$0.713-0.008-1.1%$0.730$0.737$0.701191,700
$0.721+0.008+1.1%$0.700$0.757$0.700437,500
$0.713-0.027-3.6%$0.751$0.779$0.690450,300
$0.740-0.030-3.9%$0.780$0.797$0.740246,900
$0.770+0.009+1.2%$0.744$0.797$0.730461,200
$0.761+0.026+3.5%$0.760$0.820$0.730639,300
$0.735-0.004-0.5%$0.758$0.758$0.720354,200
$0.739-0.012-1.6%$0.751$0.780$0.730428,500
$0.751-0.070-8.5%$0.833$0.847$0.740952,200
$0.821+0.019+2.4%$0.818$0.854$0.800618,671
$0.802-0.018-2.3%$0.820$0.845$0.800434,896
$0.820+0.011+1.4%$0.800$0.850$0.800345,600
$0.809-0.015-1.8%$0.820$0.860$0.780502,500

Splits

2 splits since 2017 · NASDAQ:DARE · every price before a split is adjusted for it

DayRatioWhat
1-for-12Consolidation
1-for-10Consolidation
Ticker
NASDAQ:DARE
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Dare Bioscience, Inc. news

Dare Bioscience, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
42 in the last 12 months · 186 in all · newest Nov 16, 2026 · oldest 2019
Calls
26 calls with a replay · 26 with a transcript · latest Nov 16, 2026
Decks
55 decks · latest Oct 1, 2026

Where Dare Bioscience, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:DARE · Home listing · This pageNASDAQUnited StatesUSD
BOATS:DAREBOATSUnited StatesUSD

Valuation

EV/sales −1.9× against a median of 6.5×: the lowest of 3 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$2.65M USD
P/E
Loss
EV/sales
−1.9×
EV/EBITDA
Negative EBITDA
Price/book
3.4×
Gross margin
−12.9%
Operating margin
−746.1%
Net margin
−749.8%
Debt to equity
0.4×
Beta vs S&P 500
1.34

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Dare Bioscience, Inc. · NASDAQ:DAREUS$8.01M−US$2.65Mn/a−1.9×n/a3.4×−749.8%0.4×1.34
Brainstorm Cell Therapeutics Inc. · OTC:BCLIUS$8.31MUS$10.08Mn/an/an/an/an/an/a0.40
Quantum Biopharma Ltd. Subordinate Voting Shares Class B · NASDAQ:QNTMUS$8.29M−US$3.20Mn/an/an/a0.7×n/a0.1×1.05
Moleculin Biotech, Inc. · NASDAQ:MBRXUS$8.22MUS$1.04Mn/an/an/a0.6×n/a0.0×0.42
IN8bio, Inc. · NASDAQ:INABUS$8.19M−US$3.03Mn/an/an/a0.6×n/a0.2×1.25
Intensity Therapeutics, Inc. · NASDAQ:INTSUS$8.19M−US$220,086n/an/an/a1.1×n/a0.0×1.30
Palatin Technologies, Inc. · AMEX:PTNUS$8.16MUS$4.58Mn/a12.7×n/a4.0×n/a0.1×0.61
Cellectar Biosciences, Inc. · NASDAQ:CLRBUS$8.00M−US$15.05Mn/an/an/a0.4×n/a0.1×1.71
Immuron Limited · ASX:IMCUS$7.91MUS$1.94Mn/a0.4×n/a1.1×−49.8%0.0×n/a
Phio Pharmaceuticals Corp. · NASDAQ:PHIOUS$7.84M−US$2.77Mn/an/an/a0.9×n/a0.0×1.24
Vivesto AB · OMXSTO:VIVEUS$7.76MUS$6.12Mn/an/an/a0.5×n/a0.0×n/a
Median of the othersUS$8.17MUS$408,0906.5×0.7×−49.8%0.0×1.15

Forecasts

3 strong buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
6.33 USD · Analysts' mean
EPS, year to Dec 2026
-0.79 · 2 analysts
Revenue, year to Dec 2026
418.8K · 2 analysts

Team and board

Officers

OfficerRole
Sabrina Martucci JohnsonChief Executive Officer & President
Elizabeth ProosVice President, Product Development
Jennifer KiangVice President, Corporate Affairs and Development
Jessica HathewayVice President, Clinical Operations
Mark WaltersVice President, Operations
Nicolas PacelliVice President, Alliance Management and Business Development
Robert CharboneauVice President, Manufacturing & Supply Chain
David FriendChief Scientific Officer
MarDee Haring-LaytonChief Accounting Officer

Board

DirectorRole
Gregory MatzChair of the Audit
Susan L. KelleyChair of the Nominating and Governance
William H. RastetterChairman of the Board
Jessica GrossmanDirector
Robin SteeleDirector

Events

Calls

CallWhenStatus
Dare Bioscience (NASDAQ:DARE) Q3 2026 Earnings CallMon, Nov 16, 2026 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q2 2026 Earnings CallThu, Aug 13, 2026 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q1 2026 Earnings CallThu, May 14, 2026 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q4 2025 Earnings CallThu, Mar 26, 2026 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q3 2025 Earnings CallThu, Nov 13, 2025 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q2 2025 Earnings CallThu, Aug 14, 2025 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q1 2025 Earnings CallTue, May 13, 2025 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q4 2024 Earnings CallMon, Mar 31, 2025 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q3 2024 Earnings CallThu, Nov 14, 2024 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q2 2024 Earnings CallMon, Aug 12, 2024 · 4:30 PM ETReplay
All 26 calls
CallWhenStatus
Dare Bioscience (NASDAQ:DARE) Q1 2024 Earnings CallTue, May 14, 2024 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q4 2023 Earnings CallThu, Mar 28, 2024 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q3 2023 Earnings CallThu, Nov 09, 2023 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q1 2023 Earnings CallThu, May 11, 2023 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q4 2022 Earnings CallThu, Mar 30, 2023 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q3 2022 Earnings CallThu, Nov 10, 2022 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q2 2022 Earnings CallTue, Aug 09, 2022 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q1 2022 Earnings CallThu, May 12, 2022 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q4 2021 Earnings CallThu, Mar 31, 2022 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q3 2021 Earnings CallWed, Nov 10, 2021 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q2 2021 Earnings CallThu, Aug 12, 2021 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q1 2021 Earnings CallThu, May 13, 2021 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q4 2020 Earnings CallWed, Mar 31, 2021 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q3 2020 Earnings CallThu, Nov 12, 2020 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q2 2020 Earnings CallWed, Aug 12, 2020 · 4:30 PM ETReplay
Dare Bioscience (NASDAQ:DARE) Q1 2020 Earnings CallThu, May 14, 2020 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 16, 2026 · After close−26.6%
Q2 2026Aug 13, 2026 · After close−32.1%
Q1 2026May 14, 2026 · After close−24.1%
Q4 2025Mar 27, 2026+21.2%
Q3 2025Nov 13, 2025 · After close−1.6%
Q2 2025Aug 14, 2025 · After close+6.3%
Q1 2025May 13, 2025 · After close0.0%
Q4 2024Mar 26, 2025 · Before open−0.1%
Q3 2024Nov 14, 2024 · After close−10.0%
Q2 2024Aug 12, 2024 · After close+20.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · Before open−0.1%
Q4 2023Mar 28, 2024 · Before open−10.7%
Q3 2023Nov 9, 2023 · After close+0.3%
Q2 2023Aug 10, 2023 · Before open−2.3%
Q1 2023May 11, 2023 · Before open0.0%
Q4 2022Mar 30, 2023 · Before open+1.9%
Q3 2022Nov 10, 2022 · Before open−2.2%
Q2 2022Aug 9, 2022 · Before open−2.4%
Q1 2022May 12, 2022 · Before open+9.6%
Q4 2021Mar 31, 2022 · Before open+1.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck40 slidesOct 1, 2026
Investor Presentation (July 2026)Investor deck39 slidesJul 13, 2026
Investor Presentation (June 2026)Investor deck38 slidesJun 22, 2026
Investor Presentation (April 2026)Investor deck36 slidesApr 22, 2026
Investor Presentation (March 2026)Investor deck30 slidesMar 2, 2026
Investor Presentation (January 2026)Investor deck30 slidesJan 6, 2026
Investor Presentation (September 2025)Investor deck49 slidesSep 2, 2025
Investor Presentation (June 2025)Investor deck45 slidesJun 9, 2025
Investor Presentation (February 2025)Investor deck41 slidesFeb 10, 2025
Investor Presentation (January 2025)Investor deck39 slidesJan 13, 2025
Show 50 decks
DeckKindSlidesDate
Investor Presentation (October 2024)Investor deck41 slidesOct 25, 2024
Investor Presentation (January 2024)Investor deck37 slidesJan 8, 2024
Investor Presentation (October 2023)Investor deck56 slidesOct 16, 2023
Investor Presentation (September 2023)Investor deck64 slidesSep 11, 2023
Investor Presentation (March 2023)Investor deck52 slidesMar 13, 2023
Investor Presentation (February 2023)Investor deck54 slidesFeb 6, 2023
Investor Presentation (January 2023)Investor deck54 slidesJan 9, 2023
Investor Presentation (November 2022)Investor deck50 slidesNov 3, 2022
Investor Presentation (October 2022)Investor deck50 slidesOct 17, 2022
Investor Presentation (September 2022)Investor deck47 slidesSep 12, 2022
Investor Presentation (July 2022)Investor deck46 slidesJul 25, 2022
Investor Presentation (May 2022)Investor deck46 slidesMay 23, 2022
Investor Presentation (March 2022)Investor deck46 slidesMar 7, 2022
Investor Presentation (January 2022)Investor deck46 slidesJan 10, 2022
Investor Presentation (December 2021)Investor deck46 slidesDec 8, 2021
Investor Presentation (September 2021)Investor deck45 slidesSep 30, 2021
Investor Presentation (September 2021)Investor deck42 slidesSep 9, 2021
Investor Presentation (June 2021)Investor deck42 slidesJun 30, 2021
Investor Presentation (May 2021)Investor deck42 slidesMay 17, 2021
Investor Presentation (April 2021)Investor deck48 slidesApr 8, 2021
Investor Presentation (March 2021)Investor deck49 slidesMar 8, 2021
Investor Presentation (February 2021)Investor deck49 slidesFeb 16, 2021
Investor Presentation (January 2021)Investor deck50 slidesJan 11, 2021
Investor Presentation (December 2020)Investor deck40 slidesDec 9, 2020
Investor Presentation (November 2020)Investor deck38 slidesNov 18, 2020
Investor Presentation (October 2020)Investor deck38 slidesOct 6, 2020
Investor Presentation (September 2020)Investor deck38 slidesSep 9, 2020
Investor Presentation (June 2020)Investor deck38 slidesJun 8, 2020
Investor Presentation (April 2020)Investor deck40 slidesApr 27, 2020
Investor Presentation (March 2020)Investor deck40 slidesMar 16, 2020
Investor Presentation (February 2020)Investor deck39 slidesFeb 10, 2020
Investor Presentation (January 2020)Investor deck39 slidesJan 9, 2020
Investor Presentation (October 2019)Investor deck30 slidesOct 2, 2019
Investor Presentation (September 2019)Investor deck40 slidesSep 9, 2019
Investor Presentation (July 2019)Investor deck46 slidesJul 22, 2019
Investor Presentation (June 2019)Investor deck14 slidesJun 3, 2019
Investor Presentation (May 2019)Investor deck74 slidesMay 20, 2019
Investor Presentation (April 2019)Investor deck78 slidesApr 1, 2019
Investor Presentation (March 2019)Investor deck78 slidesMar 5, 2019
Investor Presentation (February 2019)Investor deck78 slidesFeb 11, 2019

This page holds 50 of 55 decks. Open Decks

Open Decks

Financings

RaiseDate
Registered direct offering of common stock (or pre-funded warrants), with concurrent private placement of Series A and Series B warrants
Announced: US$6M · US$1.37 a share · Warrants at US$1.37 for 60 months · Ladenburg Thalmann & Co. Inc.
Dealers: Ladenburg Thalmann & Co. Inc. (lead)
Aug 17, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Cerulean Pharma Inc. Priced at US$7.00 a share on Apr 10, 2014.

Price
US$7.00 a share
Shares offered
8,500,000 shares of common stock
Offering size
US$59.5 million
Underwriters' option
Up to 1,275,000 more shares
Underwriters
Leerink Partners, Canaccord Genuity, JMP Securities, Wedbush PacGrow Life Sciences · In the order on the cover
Shares delivered
On or about Apr 15, 2014

Steps

StepWhen
Draft sent to the SEC in confidenceJan 30, 2014
Filed publiclyMar 10, 2014
Amended twiceNewest Mar 31, 2014
Shares registered with an exchangeApr 4, 2014
Declared effective by the SECApr 10, 2014
Final prospectus, with the priceApr 14, 2014

Open IPO · From the cover of the final prospectus (424B4) filed Apr 14, 2014

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.03M9.78K2.81M10.0M00000766.0K
Cost of revenue295.8K021.6M47.6K100.0K83.3K11.1K625.0K0400.0K
Gross profit-1.42M-14.3M-18.8M10.0M-100.0K-83.3K-11.1K-2.44K0366.0K
Research and development5.52M14.3M21.5M30.0M30.6M20.8M8.55M6.41M984.7K72.7K
Selling, general and administrative8.76M9.16M11.3M11.2M7.79M6.11M5.80M5.28M2.71M10.4M
Operating income-13.6M-23.5M-30.9M-31.4M-39.1M-27.4M-14.3M-16.9M-11.2M-630.6K
Depreciation and amortization1.63M42.3K38.4K24.2K26.4K43.2K11.1K2.44K0261.0K
EBITDA-11.9M-23.4M-30.9M-31.4M-39.0M-27.4M-14.3M-16.9M-11.2M-369.6K
Interest expense822.7K437.8M372.4K000322.6K42.1K
Income before tax-13.5M-4.05M-30.2M-30.9M-38.7M-27.4M-14.3M-16.8M-11.5M-673.0K
Income tax00000003.20K086.0K
Net income-13.4M-4.05M-30.2M-30.9M-38.7M-27.4M-14.3M-16.7M-11.5M-672.7K
Earnings per share, basic-1.20-0.48-4.15-0.37-0.63-0.91-0.97-1.573.56-0.81
Earnings per share, diluted-1.20-0.48-4.15-0.37-0.63-0.91-0.97-1.573.56-0.81

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents24.7M15.7M10.5M34.7M51.7M4.67M4.78M6.81M7.56M44.6K
Short-term investments15.7B00
Receivables573.1K230.0K949.2K1.70M0460.2K555.2K31.0K284.2K823.0K
Inventory-2.47B-1.85B-1.11B-402.7M311.6K-1.84M
Current assets27.1M18.4M17.5M43.0M55.3M6.98M6.44M7.24M8.35M44.6K
Property, plant and equipment1.56M1.34M656.0K64.9K26.0K37.9K63.5K9.40K0668.0K
Goodwill05.20M0
Total assets32.5M22.1M21.3M43.8M55.8M7.55M7.44M7.83M14.3M44.6K
Accounts payable1.20M1.46M3.39M2.03M2.10M1.02M1.08M459.7K308.2K1.45M
Current liabilities23.7M21.6M20.5M31.6M16.1M7.66M5.61M1.09M966.7K755.2K
Long-term debt04.44M
Total debt2.66M4.05K1.40M488.7K270.5K756.8K800.5K12.8M
Total liabilities29.6M28.1M26.3M32.7M17.1M8.70M7.00M1.10M967.0K755.2K
Shareholders' equity2.84M-6.01M-5.05M11.1M38.8M-1.15M440.8K6.73M13.3M-710.6K
Shares outstanding14.5M8.70M8.33M84.8M83.9M41.6M19.7M11.4M6.05M910.0K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-9.89M5.47M-38.9M-18.1M-28.8M-25.2M-13.3M-10.3M-2.54M-372.3K
Capital spending-385.3K-573.0K-629.4K-63.1K-14.5K-17.6K0-11.8K0-535.0K
Free cash flow-10.3M4.90M-39.5M-18.2M-28.8M-25.3M-13.3M-10.3M-2.54M-907.3K
Cash from investing-385.3K-573.0K-629.4K-63.1K-14.5K-17.6K6.14M-518.8K9.92M-418.0K
Cash from financing19.3M354.5K15.6M1.34M75.8M25.1M5.15M10.1M155.0K197.5K
Dividends paid-6.86M-789.6M00
Share buybacks24.8M5.15M10.1M0918.0K
Change in cash9.01M5.19M-23.9M-17.0M47.0M-110.6K-2.03M-754.0K7.52M-174.8K

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 20, 2026Insider tradeSEC
144 · Notice of proposed saleNov 19, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 16, 2026ResultsSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportNov 12, 2026Meeting outcomeSEC
DEFA14A · Additional proxy materialOct 27, 2026Meeting noticeSEC
DEF 14A · Proxy statementOct 6, 2026Meeting noticeSEC
8-K · Current reportOct 2, 2026Current reportSEC
8-K · Current reportOct 1, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
PRE 14A · Preliminary proxy statementSep 23, 2026Meeting noticeSEC
8-K · Current reportSep 11, 2026Current reportSEC
8-K · Current reportSep 9, 2026Current reportSEC
424B3 · ProspectusSep 4, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 4, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeAug 28, 2026Big-stake noticeSEC
S-1 · Registration statementAug 26, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeAug 24, 2026Big-stake noticeSEC
DAug 19, 2026Other filingsSEC
253G2Aug 19, 2026Other filingsSEC
8-K · Current reportAug 17, 2026Material contractSEC
424B5 · ProspectusAug 17, 2026Offer documentSEC
8-K · Current reportAug 13, 2026ResultsSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportJul 24, 2026Current reportSEC
253G2Jul 17, 2026Other filingsSEC
8-K · Current reportJul 17, 2026Current reportSEC
8-K · Current reportJul 13, 2026Current reportSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
S-8 · Registration statement for employee plansJun 23, 2026Offer documentSEC
8-K · Current reportJun 22, 2026Current reportSEC
8-K · Current reportJun 12, 2026Management or board changeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
DEFA14A · Additional proxy materialJun 1, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialJun 1, 2026Meeting noticeSEC
8-K · Current reportMay 18, 2026FinancingSEC
253G2May 14, 2026Other filingsSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
8-K · Current reportMay 7, 2026FinancingSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
8-K · Current reportApr 22, 2026Current reportSEC
8-K · Current reportApr 20, 2026FinancingSEC
8-K · Current reportApr 17, 2026Management or board changeSEC
PRE 14A · Preliminary proxy statementApr 17, 2026Meeting noticeSEC
8-K · Current reportApr 13, 2026FinancingSEC
QUALIFApr 2, 2026Other filingsSEC
1-A POSMar 27, 2026Other filingsSEC
253G2Mar 27, 2026Other filingsSEC
10-K · Annual reportMar 26, 2026Annual reportSEC
8-K · Current reportMar 26, 2026ResultsSEC
8-K · Current reportMar 17, 2026FinancingSEC
8-K · Current reportMar 9, 2026FinancingSEC
8-K · Current reportMar 2, 2026Current reportSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
8-K · Current reportJan 29, 2026FinancingSEC
253G1Jan 7, 2026Other filingsSEC
8-K · Current reportJan 6, 2026Current reportSEC
QUALIFJan 6, 2026Other filingsSEC
1-A/ADec 29, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedDec 23, 2025Big-stake noticeSEC
8-K · Current reportDec 1, 2025Current reportSEC
1-ANov 25, 2025Other filingsSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeOct 6, 2025Big-stake noticeSEC
4 · Change in ownershipSep 4, 2025Insider tradeSEC
8-K · Current reportSep 2, 2025Current reportSEC
S-8 · Registration statement for employee plansAug 14, 2025Offer documentSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
8-K · Current reportJul 25, 2025Current reportSEC
8-K · Current reportJul 18, 2025Current reportSEC
8-K · Current reportJul 14, 2025Current reportSEC
4 · Change in ownershipJul 10, 2025Insider tradeSEC
4 · Change in ownershipJul 10, 2025Insider tradeSEC
4 · Change in ownershipJul 10, 2025Insider tradeSEC
4 · Change in ownershipJul 10, 2025Insider tradeSEC
4 · Change in ownershipJul 10, 2025Insider tradeSEC
8-K · Current reportJul 9, 2025Management or board changeSEC
8-K · Current reportJun 25, 2025Current reportSEC
DEFA14A · Additional proxy materialJun 12, 2025Meeting noticeSEC
8-K · Current reportJun 9, 2025Current reportSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
8-K · Current reportMay 13, 2025ResultsSEC
ARS · Annual report to shareholdersApr 24, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2025Meeting noticeSEC
8-K · Current reportApr 11, 2025Current reportSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
8-K · Current reportMar 31, 2025ResultsSEC
8-K · Current reportFeb 14, 2025Current reportSEC
8-K · Current reportFeb 10, 2025Current reportSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
4 · Change in ownershipJan 31, 2025Insider tradeSEC
8-K · Current reportJan 13, 2025Current reportSEC
8-K · Current reportDec 16, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveNov 27, 2024Other filingsSEC
424B3 · ProspectusNov 26, 2024Offer documentSEC
DNov 22, 2024Other filingsSEC
CORRESP · Letter to the SECNov 22, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 19, 2024Other filingsSEC
S-1 · Registration statementNov 15, 2024Offer documentSEC
8-K · Current reportNov 14, 2024ResultsSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportOct 25, 2024Current reportSEC
8-K · Current reportOct 23, 2024Material contractSEC
8-K · Current reportOct 21, 2024Material contractSEC
UPLOAD · Letter from the SECOct 8, 2024Other filingsSEC
CORRESP · Letter to the SECSep 10, 2024Other filingsSEC
UPLOAD · Letter from the SECAug 30, 2024Other filingsSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
8-K · Current reportJul 19, 2024Current reportSEC
8-K · Current reportJun 27, 2024Current reportSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
8-K · Current reportJun 7, 2024Meeting outcomeSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
EFFECT · Notice that a registration is effectiveMay 13, 2024Other filingsSEC
424B5 · ProspectusMay 10, 2024Offer documentSEC
CORRESP · Letter to the SECMay 8, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveMay 2, 2024Other filingsSEC
424B3 · ProspectusMay 1, 2024Offer documentSEC
8-K · Current reportApr 30, 2024Acquisition or disposalSEC
CORRESP · Letter to the SECApr 29, 2024Other filingsSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 16, 2024Meeting noticeSEC
UPLOAD · Letter from the SECApr 3, 2024Other filingsSEC
UPLOAD · Letter from the SECApr 3, 2024Other filingsSEC
S-3 · Registration statementMar 29, 2024Offer documentSEC
S-3 · Registration statementMar 29, 2024Offer documentSEC
424B5 · ProspectusMar 28, 2024Offer documentSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
8-K · Current reportMar 28, 2024ResultsSEC
4 · Change in ownershipMar 14, 2024Insider tradeSEC
4 · Change in ownershipMar 14, 2024Insider tradeSEC
4 · Change in ownershipMar 14, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 29, 2024Insider tradeSEC
8-K · Current reportJan 26, 2024Management or board changeSEC
8-K · Current reportJan 19, 2024Current reportSEC
8-K · Current reportJan 8, 2024Current reportSEC
DDec 26, 2023Other filingsSEC
8-K · Current reportDec 26, 2023Material contractSEC
8-K · Current reportDec 20, 2023Current reportSEC
8-K · Current reportNov 9, 2023Current reportSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
8-K · Current reportNov 1, 2023Current reportSEC
8-K · Current reportOct 16, 2023Current reportSEC
8-K · Current reportSep 11, 2023Current reportSEC
424B5 · ProspectusAug 30, 2023Offer documentSEC
8-K · Current reportAug 30, 2023Material contractSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
8-K · Current reportAug 10, 2023ResultsSEC
8-K · Current reportJul 21, 2023Current reportSEC
8-K · Current reportJul 5, 2023Material contractSEC
8-K · Current reportJun 22, 2023Meeting outcomeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
4 · Change in ownershipJun 21, 2023Insider tradeSEC
8-K · Current reportJun 5, 2023Current reportSEC
10-Q · Quarterly reportMay 11, 2023Quarterly reportSEC
8-K · Current reportMay 11, 2023ResultsSEC
ARS · Annual report to shareholdersMay 1, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 27, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 27, 2023Meeting noticeSEC
424B5 · ProspectusMar 31, 2023Offer documentSEC
8-K · Current reportMar 31, 2023Material contractSEC
10-K · Annual reportMar 30, 2023Annual reportSEC
8-K · Current reportMar 30, 2023ResultsSEC
8-K · Current reportMar 13, 2023Current reportSEC
8-K · Current reportFeb 6, 2023Current reportSEC
8-K · Current reportJan 27, 2023Current reportSEC
4 · Change in ownershipJan 26, 2023Insider tradeSEC
4 · Change in ownershipJan 26, 2023Insider tradeSEC
4 · Change in ownershipJan 26, 2023Insider tradeSEC
8-K · Current reportJan 25, 2023Current reportSEC

This page holds 200 of 783 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Dare Bioscience, Inc.’s releases · as of Nov 13, 2026

Common shares
19,669,083
Fully diluted
19,669,083

Fully diluted

LineSharesAs of
Common shares19,669,083Nov 13, 2026

Share count over time

CountShares
Nov 13, 202619,669,083

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard727K3.7%US$620KSep 30, 2026
UBS240K1.2%US$204KSep 30, 2026
US Bancorp \de\221K1.1%US$189KSep 30, 2026
Geode Capital152K0.77%US$130KSep 30, 2026
BlackRock62,1620.32%US$53,043Sep 30, 2026
State Street47,4150.24%US$40,459Sep 30, 2026
Citadel45,1420.23%US$38,520Sep 30, 2026
XTX Topco Ltd37,3760.19%US$31,893Sep 30, 2026
Hrt Financial LP37,3420.19%US$31,000Sep 30, 2026
Northern Trust34,2090.17%US$29,191Sep 30, 2026
All 36 holders
HolderSharesOf the companyValueAs of
Virtu Financial LLC33,5060.17%US$29,000Sep 30, 2026
Two Sigma19,6560.10%US$16,772Sep 30, 2026
Garde Capital, Inc.16,2200.08%US$13,841Sep 30, 2026
LPL Financial LLC14,8890.08%US$12,705Sep 30, 2026
Raymond James Financial Inc14,6280.07%US$12,483Sep 30, 2026
T. Rowe Price13,3180.07%US$12,000Sep 30, 2026
Objectivity Squared, LLC10,9150.06%US$9,314Sep 30, 2026
Farther Finance Advisors, LLC9,4080.05%US$8,028Sep 30, 2026
Tower Research Capital LLC (TRC)1,733<0.01%US$1,479Sep 30, 2026
PNC Financial Services Group, Inc.1,100<0.01%US$938Sep 30, 2026
IFS Advisors, LLC950<0.01%US$810Sep 30, 2026
SBI Securities Co., Ltd.715<0.01%US$610Sep 30, 2026
RBC596<0.01%US$1,000Sep 30, 2026
Entrust Financial LLC500<0.01%US$427Sep 30, 2026
Jacobi Capital Management LLC434<0.01%US$370Sep 30, 2026
Jones Financial Companies Lllp396<0.01%US$307Sep 30, 2026
Keating Financial Advisory Services, Inc.107<0.01%US$91Sep 30, 2026
Caldwell Sutter Capital, Inc.100<0.01%US$85Sep 30, 2026
Mather Group, LLC.84<0.01%US$72Sep 30, 2026
JPMorgan19<0.01%US$15Sep 30, 2026
Inspire Investing, LLC14<0.01%US$12Sep 30, 2026
Fidelity6<0.01%US$5Sep 30, 2026
Compass Financial Management LLC5<0.01%US$4Sep 30, 2026
Barclays2<0.01%US$2Sep 30, 2026
Putney Financial Group LLC1<0.01%US$1Sep 30, 2026
Wells Fargo00.00%Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund471K2.4%US$995KJun 30, 2026
Vanguard Extended Market Index Fund161K0.82%US$341KJun 30, 2026
Fidelity Extended Market Index Fund78,0500.40%US$174KMay 31, 2026
iShares Micro-Cap ETF45,2890.23%US$95,560Jun 30, 2026
Fidelity Series Total Market Index Fund32,4730.17%US$72,415May 31, 2026
Fidelity Total Market Index Fund15,3260.08%US$34,177May 31, 2026
Vanguard Balanced Index Fund8,0060.04%US$16,893Jun 30, 2026
Fidelity Nasdaq Composite Index Fund7,5710.04%US$16,883May 31, 2026
1290 VT Micro Cap Portfolio2,9780.02%US$6,284Jun 30, 2026
Total Stock Market Index Trust626<0.01%US$1,321Jun 30, 2026

Insider trades

TradeTradeSharesPriceValueDate
Rastetter William H
Director
Sale859USD 0.45US$382Nov 19, 2026

Big stakes

StakeStakeSharesDateFiling
L1 Capital Global Opportunities Master Fund, Ltd.9.99%2.03MAug 17, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Cheryl R. Blanchard
Other companies: Xilio Therapeutics, Inc. (Board Member · Since at least Apr 15, 2026); Vigil Neuroscience Inc (Director · Since at least Jan 6, 2022); Anika Therapeutics Inc. (Director · Since at least Aug 31, 2018); Neuronetics, Inc. (Director · Feb 13, 2019 – May 26, 2020 · Past); SeaSpine Holdings Corp (Director · Jul 1, 2015 – May 30, 2018 · Past); Zimmer Biomet Holdings, Inc. (Sr. VP, Chief Scientific Off. · Feb 17, 2011 – Mar 19, 2012 · Past)
Director · Nov 20, 2019 – Jun 21, 2023 · Past
William McKee
Other companies: Assertio Holdings, Inc. (Director · Since at least May 19, 2020); C4 Therapeutics, Inc. (Chief Financial Officer · Oct 1, 2020 – Oct 6, 2020 · Past); Rein Therapeutics, Inc. (Director · Jun 19, 2019 – Jun 15, 2022 · Past); Depomed Inc (Director · Mar 28, 2017 – May 8, 2018 · Past); Auxilium Pharmaceuticals Inc (Director · Mar 18, 2009 – Jan 29, 2015 · Past); Barr Pharmaceuticals Inc (EVP, CFO · Jan 3, 2006 – Dec 23, 2008 · Past)
Director · Apr 10, 2014 – Jan 3, 2017 · Past
Stuart Arbuckle
Other companies: Praxis Precision Medicines, Inc. (Director · Since at least Jan 8, 2026); Alnylam Pharmaceuticals, Inc. (Director · Since at least Jan 5, 2026); Rhythm Pharmaceuticals, Inc. (Director · Since at least Jul 23, 2019); Vertex Pharmaceuticals Incorporated (EVP, COO · Since at least May 25, 2016); ImmunoGen Inc (Director · Jan 23, 2018 – Feb 12, 2024 · Past)
Director · Jun 22, 2016 – Jan 3, 2017 · Past
Alejandra Carvajal
Other companies: CytomX Therapeutics, Inc. (Chief Legal Officer · Since at least Aug 3, 2026); Mersana Therapeutics Inc (SVP, Chief Legal Officer · Since at least Apr 26, 2021); Momenta Pharmaceuticals Inc (Chief Legal Officer · Oct 5, 2018 – Oct 1, 2020 · Past)
VP, General Counsel · Jun 26, 2015 – Jan 5, 2017 · Past
David R Walt
Other companies: Quanterix Corporation (Director · Since at least Dec 6, 2017); Exicure, Inc. (Director · Sep 26, 2017 – Jun 4, 2020 · Past); Illumina, Inc. (Director · Apr 2, 2007 – Apr 7, 2016 · Past)
Director · Feb 23, 2015 – Jan 3, 2017 · Past
William H. Rastetter
Other companies: Iambic Therapeutics, Inc. (Board Chair · Since at least Oct 16, 2026); Neurocrine Biosciences, Inc. (Director · Since at least May 21, 2026); Fate Therapeutics, Inc. (Chairman · Since at least May 5, 2026)
Chairman of the Board · Since at least Jun 30, 2026
Adrian M. Senderowicz
Other companies: Puma Biotechnology Inc (Director · Since at least Aug 11, 2015); Constellation Pharmaceuticals Inc (Chief Medical Officer · Jul 18, 2018 – May 12, 2020 · Past)
SVP, Chief Medical Officer · Sep 4, 2015 – Jan 5, 2017 · Past
Lisa Walters-Hoffert
Other companies: Kiora Pharmaceuticals, Inc. (Director · Since at least Jul 1, 2024); Flux Power Holdings, Inc. (Director · Since at least Jun 28, 2019)
Chief Financial Officer · Jul 19, 2017 – Jan 24, 2023 · Past
Steven Edward Hall
Other companies: Kymera Therapeutics, Inc. (Director · Aug 20, 2020 – Jun 16, 2021 · Past); Forma Therapeutics Holdings Inc (Director · Jun 18, 2020 – Jun 23, 2020 · Past)
Director · Apr 10, 2014 – Jun 22, 2016 · Past
Christopherd T Guiffre
Other companies: Pear Therapeutics Inc (CFO, COO, Treas., & Asst. Sec. · Dec 3, 2021 – Feb 15, 2023 · Past)
Chief Executive Officer, Director · Jun 30, 2016 – Jan 6, 2017 · Past
All 26 people
PersonSeat
MarDee Haring-Layton
Other companies: e.Digital Corporation (Chief Financial Officer · Dec 5, 2011 – Mar 30, 2015 · Past)
Chief Accounting Officer · Since at least Jan 26, 2024
Roger Hawley
Other companies: Zogenix Inc (Director · Jul 13, 2016 – Mar 29, 2019 · Past)
Director · Jul 19, 2017 – Jun 13, 2019 · Past
David FriendChief Scientific Officer · Since at least Sep 14, 2026
Edward Graeme GarmeySr. VP, Chief Medical Officer · Apr 10, 2014 – Feb 5, 2015 · Past
Elizabeth ProosVice President, Product Development · Since at least Nov 4, 2026
Gregory MatzChair of the Audit · Since at least Jul 2, 2026
Jennifer KiangVice President, Corporate Affairs and Development · Since at least Nov 4, 2026
Jessica GrossmanDirector · Since at least Jun 30, 2026
Jessica HathewayVice President, Clinical Operations · Since at least Nov 4, 2026
John A FairChief Commercial Officer · Mar 6, 2020 – Mar 12, 2024 · Past
Mark WaltersVice President, Operations · Since at least Nov 4, 2026
Nicolas PacelliVice President, Alliance Management and Business Development · Since at least Nov 4, 2026
Robert CharboneauVice President, Manufacturing & Supply Chain · Since at least Nov 4, 2026
Robin SteeleDirector · Since at least Jul 19, 2017
Sabrina Martucci JohnsonChief Executive Officer & President · Since at least Oct 30, 2026
Susan L. KelleyDirector · Since at least Jun 30, 2026

Open People

Log in to ask 6ix AI your own questions about Dare Bioscience, Inc.